To learn more, researchers investigated the post-vaccination antibody response of Pfizer/BioNTech and CoronaVac vaccines in 124 adults (mean age 42 to 63 years) with severe obesity who visited China. Center for Obesity at Istanbul-Cerrahpasa University, Cerrahpaşa Medical College Hospital, between August and November 2021. They also recruited a control group of 166 adults of normal weight (BMI less than 25 kg). /m2, mean age 39 to 47) attended the Cerrahpasa Hospital Immunization Unit.
The researchers measured antibody levels in blood samples taken from patients and normal weight controls who received two doses of Pfizer/BioNTech or CoronaVac vaccine and received the second dose 4 weeks ago. there. Participants were classified by history of infection, whether or not they had previously had COVID-19 (confirmed by their antibody profile).
Results of the study
Overall, 130 participants received two doses of Pfizer/BioNTech and 160 participants received two doses of CoronaVac, of which 70 had prior SARS-CoV-2 infection.
In subjects without prior SARS-CoV-2 infection and vaccinated with Pfizer/BioNTech, severely obese patients had antibody levels three times lower than normal-weight controls (mean 5,823 vs 19,371) AU/mL).
Similarly, in participants without prior SARS-CoV-2 infection and receiving the CoronaVac vaccine, severely obese patients had 27-fold lower antibody levels compared with normal-weight controls (mean 178 vs 4.894 AU/mL).
However, in people with previous infection with SARS-CoV-2, antibody levels in severely obese patients immunized with Pfizer/BioNTech or CoronaVac were not significantly different from normal-weight controls (mean 39,043 vs 14,115 AU/mL and 3,221 vs 7,060 AU, respectively) /ml).
Interestingly, the analyzes found that in severely obese patients, with and without previous SARS-CoV-2 infection, antibody levels were significantly higher in those vaccinated with Pfizer/BioNTech compared with with people vaccinated with CoronaVac.
Professor Yumuk said: “These results provide new information on the antibody response to the SARS-CoV-2 vaccine in severely obese individuals and reinforce the importance of prioritizing and enhancing vaccine collection in this vulnerable population. “Our study confirms that immune memory induced by previous infection changes the way people respond to vaccination and shows that two doses of the Pfizer/BioNTech vaccine can generate multiple antibodies. significantly more than CoronaVac in severely obese individuals, regardless of history of infection.However, further research is needed to determine whether these higher levels of antibodies provide better protection against COVID-19 or not.”